The Latest Analyst Ratings for Immunogen
Portfolio Pulse from Benzinga Insights
Immunogen (NASDAQ: IMGN) has received positive analyst ratings in the last quarter, with an average 12-month price target of $17.0, a high of $19.00, and a low of $15.00. The average price target has increased by 41.67% over the past month.
June 06, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunogen has received positive analyst ratings, with an average 12-month price target of $17.0, which has increased by 41.67% over the past month.
The positive analyst ratings and the significant increase in the average price target over the past month indicate a bullish sentiment towards Immunogen. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100